Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

• Status: Completed
• Trial end date: 2006-08-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell or bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by bone marrow or peripheral stem cell transplantation and/or biological therapy in treating patients who have stage III, stage IV, or recurrent mantle cell lymphoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Northwestern University
• Collaborator: National Cancer Institute (NCI)
• Treatments: Aldesleukin; Busulfan; Cyclophosphamide; Cytarabine; Doxorubicin; Interferon-alpha; Interferons; Leucovorin; Levoleucovorin; Liposomal doxorubicin; Methotrexate; Prednisone; Teniposide; Vincristine

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed stage III, IV, or recurrent mantle cell lymphoma

• CD5 positive OR

• Evidence of bcl-1 oncogene overexpression

• Measurable or evaluable disease with at least one of the following:

• Clear cut radiographic findings

• Clearly defined bidimensional defect or mass at least 2 cm in diameter on radionuclide or CT scan

• Enlarged spleen extending at least 2 cm below costal margin with lymphomatous involvement only

• Enlarged liver with proof of lymphoma by biopsy

• CNS involvement allowed

• Fully HLA matched donor for allogeneic transplantation

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• ECOG 0-3

Life expectancy:

• Not specified

Hematopoietic:

• Not specified

Hepatic:

• Bilirubin no greater than 3.0 mg/dL

Renal:

• Creatinine no greater than 2.0 mg/dL

Cardiovascular:

• No significant cardiac disease

Other:

• No other prior malignancies except previously treated nonmelanoma skin cancer or carcinoma in situ of the cervix

• No other medical problems that would preclude study

• HIV negative

• Not pregnant or nursing

• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• See Disease Characteristics

Chemotherapy:

• See Disease Characteristics

• Prior chemotherapy, including doxorubicin, allowed

Endocrine therapy:

• See Disease Characteristics

• Prior steroids allowed

Radiotherapy:

• See Disease Characteristics

• Prior radiotherapy allowed excluding the indicator lesions

Surgery:

• Not specified